Dr Nick Kenny Promoted as New Senior Vice President for Global Oncology Division
08 August 2008
INC Research, a therapeutically-focused contract research organization (CRO) with a process for delivering reliable results, have announced Nick Kenny, Ph.D. as the senior vice president of Oncology. Dr. Kenny began his career at INC Research in 2006 as senior project director Oncology.
“Nick was the obvious choice to step into this senior management role in oncology,” said John Potthoff, COO of INC Research. “Not only does he have impeccable therapeutic expertise, but he has been instrumental in fine tuning the methodologies that we use today in our Trusted Process for delivering high quality clinical results that meet or exceed customer expectations. We are confident that Nick can continue to build our successful oncology practice.” Dr. Kenny has 25 years of research, development and international project integration experience in the CRO and academic segments. Prior to INC Research, he held various management positions at CROs where he established the strategic direction of clinical programs, as well as global oversight of project management, clinical monitoring and regulatory staff. Prior to his move to industry, Dr. Kenny spent 15 years in endocrinology and cell biology research and teaching in the UK, Canada, and the United States where he was assistant professor in the College of Medicine at the University of Vermont. Over the past 10 years, Dr. Kenny’s drug development expertise has been primarily focused upon oncology clinical development. He is continually sought after as a subject matter expert to represent both CRO and oncology perspectives by industry publications and conferences.
“I am thrilled to be working with a CRO that is as passionate about oncology drug development as I am,” said Kenny. “INC Research has developed an incredible track record for global oncology trials. I intend to reinforce that reputation by continued advancement of the quality of service and depth of expertise the oncology practice offers to support our customers in bringing forward new treatments for cancer patients.”
